Tolerability of Rebif® (Interferon-beta 1-A) Therapy in Korean Patients With Multiple Sclerosis

• Status: Completed
• Trial end date: 2011-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This is an observational study to assess the tolerability of Rebif treatment in Korean multiple sclerosis (MS) subjects.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck KGaA; Merck KGaA, Darmstadt, Germany
• Treatments: Interferon beta-1a; Interferon-beta; Interferons

Criteria

Inclusion Criteria:

• Subjects, who are eligible for Rebif treatment according to the indication in the national label of Rebif in Korean subjects with MS. The national labels approved by Korean Regulatory Authority are:

1. Subjects with relapsing MS with two or more acute exacerbations in the previous two years

2. Subjects with secondary progressive MS with ongoing relapsing activity

• Subjects who sign the informed consent form.

Exclusion Criteria:

• Initiation of treatment in pregnancy.

• Subjects with a history of hypersensitivity to natural or recombinant interferon-ß, or to any excipients.

• Subjects with current severe depression and/or suicidal ideation.